299 related articles for article (PubMed ID: 30545626)
1. Molecular mechanisms underlying the inhibitory effects of bovine lactoferrin on osteosarcoma.
Chea C; Haing S; Miyauchi M; Shrestha M; Imanaka H; Takata T
Biochem Biophys Res Commun; 2019 Jan; 508(3):946-952. PubMed ID: 30545626
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of the inhibitory effects of bovine lactoferrin on lipopolysaccharide-mediated osteoclastogenesis.
Inubushi T; Kawazoe A; Miyauchi M; Kudo Y; Ao M; Ishikado A; Makino T; Takata T
J Biol Chem; 2012 Jul; 287(28):23527-36. PubMed ID: 22593578
[TBL] [Abstract][Full Text] [Related]
3. Lactoferrin inhibits infection-related osteoclastogenesis without interrupting compressive force-related osteoclastogenesis.
Inubushi T; Kawazoe A; Miyauchi M; Yanagisawa S; Subarnbhesaj A; Chanbora C; Ayuningtyas NF; Ishikado A; Tanaka E; Takata T
Arch Oral Biol; 2014 Feb; 59(2):226-32. PubMed ID: 24370195
[TBL] [Abstract][Full Text] [Related]
4. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
5. Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity.
Lorget F; Clough J; Oliveira M; Daury MC; Sabokbar A; Offord E
Biochem Biophys Res Commun; 2002 Aug; 296(2):261-6. PubMed ID: 12163011
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of orally administrated liposomal bovine lactoferrin on the LPS-induced osteoclastogenesis.
Yamano E; Miyauchi M; Furusyo H; Kawazoe A; Ishikado A; Makino T; Tanne K; Tanaka E; Takata T
Lab Invest; 2010 Aug; 90(8):1236-46. PubMed ID: 20421871
[TBL] [Abstract][Full Text] [Related]
7. Bovine lactoferrin improves bone status of ovariectomized mice via immune function modulation.
Malet A; Bournaud E; Lan A; Mikogami T; Tomé D; Blais A
Bone; 2011 May; 48(5):1028-35. PubMed ID: 21303707
[TBL] [Abstract][Full Text] [Related]
8. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
9. IL-1 plays an important role in the bone metabolism under physiological conditions.
Lee YM; Fujikado N; Manaka H; Yasuda H; Iwakura Y
Int Immunol; 2010 Oct; 22(10):805-16. PubMed ID: 20679512
[TBL] [Abstract][Full Text] [Related]
10. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
11. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
Ohba T; Cole HA; Cates JM; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
J Bone Miner Res; 2014 Jun; 29(6):1431-45. PubMed ID: 24443409
[TBL] [Abstract][Full Text] [Related]
13. Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling.
Golden D; Saria EA; Hansen MF
J Cell Physiol; 2015 Dec; 230(12):2951-60. PubMed ID: 25893522
[TBL] [Abstract][Full Text] [Related]
14. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
Song J; Jing Z; Hu W; Yu J; Cui X
Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin activates osteosarcoma cells that co-express RANK and RANKL.
Marley K; Bracha S; Seguin B
Exp Cell Res; 2015 Oct; 338(1):32-8. PubMed ID: 26254896
[TBL] [Abstract][Full Text] [Related]
16. Bovine lactoferrin enhances osteogenesis through Smad2/3 and p38 MAPK activation.
Inubushi T; Kosai A; Yanagisawa S; Chanbora C; Miyauchi M; Yamasaki S; Sugiyama E; Ishikado A; Makino T; Takata T
J Oral Biosci; 2020 Jun; 62(2):147-154. PubMed ID: 32464258
[TBL] [Abstract][Full Text] [Related]
17. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
18. Oral bovine lactoferrin improves bone status of ovariectomized mice.
Blais A; Malet A; Mikogami T; Martin-Rouas C; Tomé D
Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1281-8. PubMed ID: 19336659
[TBL] [Abstract][Full Text] [Related]
19. HDAC2-mediated upregulation of IL-6 triggers the migration of osteosarcoma cells.
Li J; Yan X; Tang J; Wang Y; Tang J; Wu W; Liu M
Cell Biol Toxicol; 2019 Oct; 35(5):423-433. PubMed ID: 30706385
[TBL] [Abstract][Full Text] [Related]
20. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
